首页>
外国专利>
Co-therapy comprising canagliflozin and phentermine for the treatment of obesity and obesity related disorders
Co-therapy comprising canagliflozin and phentermine for the treatment of obesity and obesity related disorders
展开▼
机译:包含卡格列净和芬特明的联合疗法,用于治疗肥胖症和与肥胖相关的疾病
展开▼
页面导航
摘要
著录项
相似文献
摘要
The present invention is directed to the use of co-therapy comprising administration of canagliflozin and phentermine for the treatment of obesity and obesity related disorders. More particularly, the present invention is directed to co-therapy for treating obesity, for promoting weight loss and/or for suppressing appetite; for treating, delaying, slowing the progression of and/or preventing metabolic disorders (including for example Type 2 diabetes mellitus); for treating, delaying, slowing the progression of and/or preventing renal or fatty liver disorders (including for example NASH, NAFLD, etc.); for treating, delaying, slowing the progression of and/or preventing sleep disorders (including for example sleep apnea); for providing cardiovascular protection; for treating, delaying, slowing the progression of and/or preventing cardiovascular events (including major adverse cardiac events (MACE) such as myocardial infarction, unstable angina, cardiovascular death, revascularization, fatal or non-fatal cerebrovascular accident, peripheral arteriopathy, aortic events, hospitalization due to congestive heart failure, etc.); and/or for extending or prolonging life span.
展开▼